Fig. 1.

(a) Mean CXCL10 concentration measured by fluorescent bead-based immunoassay was increased in untreated opsoclonus–myoclonus syndrome (OMS) (uOMS) cerebrospinal fluid (CSF) but not in paired serum. Separate statistical comparisons were made between controls, untreated OMS (uOMS) and treated OMS (tOMS); and between controls, OMS without neuroblastoma (OMS − NB), and OMS with neuroblastoma (OMS + NB). Statistical brackets with P-values above them indicate analysis of variance (anova) results; those with P-values underneath indicate t-test results. The neuroblastoma without OMS group had only five patients, so it is presented only for visual comparison. (b) CSF CXCL10 concentration as measured by Luminex versus enzyme-linked immunosorbent assay (ELISA) in entire data set. (c) Serum CXCL10 measured by Luminex versus ELISA in entire data set.